COVID-19 and SARS-CoV-2 Informational Resource Page
Menu

J&J Announce Promising Phase 3 Interim Analysis for Single-Dose COVID-19 Vaccine Candidate

1/30/2021

0 Comments

 
Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination

85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28

Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa
​

Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting

Press release link
0 Comments



Leave a Reply.

    Author

    J. Kaiser, MSc
    MDT/EMT

    RSS Feed

    Archives

    January 2021
    December 2020

    Categories

    All

    RSS Feed

Picture

​​Proudly Presented by 

  • Home
  • Testing
    • Testing Basics
    • PCR Overview >
      • PCR Tests
    • Why does testing take so long?
  • Vaccines
    • Vaccine Efficacy
    • Phases of Development
    • Vaccine Platforms >
      • Nucleic Acid / mRNA
      • Viral Vectored
      • Subunit / Protein
      • Whole Virus
  • Masks
  • Symptoms
  • Quarantine / Isolation
  • Virus Biology
    • Virus structure
    • Viral Genome
  • Mutation & Variation
  • News
  • Other Resources
  • Contact
  • Home
  • Testing
    • Testing Basics
    • PCR Overview >
      • PCR Tests
    • Why does testing take so long?
  • Vaccines
    • Vaccine Efficacy
    • Phases of Development
    • Vaccine Platforms >
      • Nucleic Acid / mRNA
      • Viral Vectored
      • Subunit / Protein
      • Whole Virus
  • Masks
  • Symptoms
  • Quarantine / Isolation
  • Virus Biology
    • Virus structure
    • Viral Genome
  • Mutation & Variation
  • News
  • Other Resources
  • Contact